引用本文
  •    [点击复制]
  •    [点击复制]
【打印本页】 【在线阅读全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 68次   下载 49 本文二维码信息
码上扫一扫!
SOX 方案新辅助化疗联合腹腔镜辅助胃癌根治术的安全性及疗效评价
潘林锋,张英杰,臧伟峰
0
浙江省舟山医院普外胃肠外科浙江 316000
摘要:
目的:探讨SOX方案新辅助化疗联合腹腔镜辅助胃癌根治术的安全性及疗效。方法:选取2017年1月—2019年1月期间我院收治的35例进展期胃癌患者为研究对象,根据患者及其家属意愿,将其分为腹腔镜辅助胃癌根治术治疗组(对照组,n=19)及SOX新辅助化疗联合腹腔镜辅助胃癌根治术治疗组(观察组,n=16)。记录两组患者化疗相关不良反应发生情况,比较两组手术相关指标、术后恢复情况、术后并发症发生率及术后1年生存率。结果:新辅助化疗后,观察组患者共计发生化疗相关不良反应15例次,严重程度以I级、Ⅱ级为主。两组患者手术时间、术中出血量、术中输血患者数及术中淋巴结清扫数目差异均无统计学意义(P>0.05),观察组根治性切除率高于对照组(93.75% vs 63.16%,P<0.05)。两组患者术后下床活动时间、肛门排气时间及住院时间差异均无统计学意义(P>0.05)。两组患者术后切口感染、腹腔感染及肺部感染发病率均无统计学意义(P>0.05);观察组患者术后1年生存率的数值高于对照组(93.75% vs 84.21%),但差异无统计学意义(P>0.05)。结论:SOX新辅助化疗联合腹腔镜辅助胃癌根治术可提高进展期胃癌患者根治性切除率,是一种安全可行的治疗方式。
关键词:  新辅助化疗  腹腔镜  胃癌根治术  进展期胃癌
DOI:10.3969/j.issn.1007-6948.2021.02.007
投稿时间:2020-07-18
基金项目:舟山市科技计划项目(2018C11042)
Safety and Efficacy of Sox Neoadjuvant Chemotherapy Combined with Laparoscopic Assisted Radical Gastrectomy for Gastric Cancer
PAN Lin-feng,ZHANG Ying-jie,ZANG Wei-feng
Department of Gastroenterological Surgery, Zhejiang Zhoushan Hospital, Zhoushan316000, China
Abstract:
Objective To investigate the safety and efficacy of Sox neoadjuvant chemotherapy combined with laparoscopic assisted radical gastrectomy for gastric cancer. Methods Thirty-five patients with advanced gastric cancer in our hospital were selected as the study objects from January 2017 to January 2019, according to the wishes of patients and their families.They were divided into two groups: laparoscopic assisted radical gastrectomy (control group, n=19) and SOX neoadjuvant chemotherapy combined with laparoscopic assisted radical gastrectomy (observation group, n=16). The incidence of chemotherapy-related adverse reactions was recorded in the observation group, and the operation related indexes, postoperative recovery, postoperative complications and 1-year survival rate were compared between the two groups. Results After neoadjuvant chemotherapy, there were 15 cases of chemotherapy-related adverse reactions in the observation group, the severity of which was mainly grade I and grade II. There was no significant difference between the two groups in operative time, intraoperative blood loss, intraoperative blood transfusion and intraoperative lymph node dissection (P>0.05). The radical resection rate of the observation group was higher than that of the control group (P<0.05). There was no significant difference between the two groups in the time of getting out of bed, anal exhaust and hospitalization (P>0.05). The incidence of incision infection, abdominal infection and hair coloring were not statistically significant in the two groups (P>0.05). The 1 year survival rate in the observation group was higher than that in the control group (93.75% vs 84.21%), but the difference was not statistically significant (P > 0 . 05 ). Conclusion SOX neoadjuvant chemotherapy combined with laparoscopic assisted radical gastrectomy can improve the radical resection rate of advanced gastric cancer, which is a safe and feasible treatment.
Key words:  Neoadjuvant chemotherapy  laparoscopy  radical gastrectomy  advanced gastric cancer

用微信扫一扫

用微信扫一扫